RYSE Asset Management, the healthcare investor supporting innovative early-stage companies transforming lives, announced it has participated in a double-digit million investment round for Curio Digital Therapeutics Inc., (Curio), an innovative US company treating postpartum depression (PPD) and other underserved women’s mental health conditions.
Read also – [Funding News] Aplantex Secures CAD$2.8 Million Financing to Accelerate its Development
Strategic investor ONCE, the nutraceuticals venture capital arm of Otsuka; Bridge Point Capital and Avestria also participated in the round.
Read also – PsychoGenics Receives $3 Million SBIR Grant to Employ AI-enabled Platforms
New Jersey based Curio Digital Therapeutics has received FDA approval for its lead product MamaLift Plus. MamaLift Plus is the women’s health first prescription digital therapeutic to receive SaMD Class2 approval. It treats postpartum depression, a complex mental health disorder affecting as many as one in seven women with a recent live birth experience.i The FDA approved MamaLift Plus is a prescription‐only digital therapeutic for patients aged 22 years and older in conjunction with clinician‐managed outpatient care. It is intended to be administered over eight weeks for the treatment of mild to moderate PPD. MamaLift is underpinned by a Connected Care platform which assesses women’s risk of depression and integrates her treatment with her existing healthcare providers. This is particularly significant for providers who are required to report on levels of depression amongst their female populations.
Curio Digital Therapeutics is currently working with health plans, insurers and corporate employee benefit plans in the US and India. They also work at a strategic level with pharma companies and others who seek to engage with Curio’s data and underlying connected care platform which spans post-natal depression, fertility and menopause.
The RYSE investment comes from its Special Opportunities Fund that focuses on the most promising early-stage investments globally between seed and series A. Dedicated to transforming lives through cutting edge digital solutions, the fund has an investment focus on digital diagnostics, digital therapeutics and medical devices that will help solve the challenges facing the NHS and other health and care delivery systems globally. The fund recently welcomed new investors including Future Care Capital, as a cornerstone investor, and established global endowments, family offices and sophisticated investors.
Vivien de Tusch-Lec, General Partner at RYSE said: “This financing is a significant milestone for RYSE Asset Management. As a clinically validated, fully scalable, revenue generating solution, Curio is taking a holistic approach to tackling women’s health by designing interventions that address behavioural management and physiological conditions across Women’s Life Cycle. We see a significant opportunity for Mama Lift Plus, and for the other products in the Company’s pipeline.”
Shailja Dixit, MD, MPH, MS, CEO and Founder of Curio Digital Therapeutics said: “Our goal has always been to provide innovative solutions for women’s health, specifically around the challenges they face with behavioral health. MamaLift Plus is the first and only digital solution that can help address the serious unmet need uniquely faced by women who have recently delivered, and help make a conscious shift in women’s health. We are grateful to have the backing of RYSE, and our committed new investors as we bring these products to new markets.”
About Curio Digital Therapeutics
Curio Digital Therapeutics is a pioneer in developing digital therapeutics solutions and interventions across the behavioral health continuum for women throughout the cycle of life. Curio aims to create a world where every woman can access a behavioral health solution at her fingertips. Curio Digital Therapeutics is reshaping maternal mental health care by leveraging proprietary algorithms, clinically validated screening tools, and personalized digital behavioral interventions to facilitate timely identification and care. Curio Digital Therapeutics aspires to make women’s health products and solutions across their life cycle.
